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Abstract
Background: Chlamydia (C.) trachomatis is the most prevalent bacterial sexually transmitted infection worldwide
and the leading cause of preventable blindness. Genetic approaches to investigate C. trachomatis have been only
recently developed due to the organism’s intracellular developmental cycle. HtrA is a critical stress response serine
protease and chaperone for many bacteria and in C. trachomatis has been previously shown to be important for
heat stress and the replicative phase of development using a chemical inhibitor of the CtHtrA activity. In this study,
chemically-induced SNVs in the cthtrA gene that resulted in amino acid substitutions (A240V, G475E, and P370L)
were identified and characterized.
Methods: SNVs were initially biochemically characterized in vitro using recombinant protein techniques to confirm
a functional impact on proteolysis. The C. trachomatis strains containing the SNVs with marked reductions in proteolysis
were investigated in cell culture to identify phenotypes that could be linked to CtHtrA function.
Results: The strain harboring the SNV with the most marked impact on proteolysis (cthtrAP370L) was detected to have a
significant reduction in the production of infectious elementary bodies.
Conclusions: This provides genetic evidence that CtHtrA is critical for the C. trachomatis developmental cycle.
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Background
Chlamydia trachomatis is the most prevalent bacterial
sexually transmitted infection worldwide and the leading
cause of preventable blindness [1, 2]. If left untreated,
chlamydial infection can lead to serious and costly condi-
tions including infertility, ectopic pregnancy, epididymitis,
and pelvic inflammatory disease. As intracellular bacteria,
the Chlamydiae are defined by their unique development
cycle where small, infectious elementary bodies (EB) in-
vade a host cell and differentiate into large, non-infectious
reticulate bodies (RB) that replicate by binary fission [3].
Due to the absence of several biosynthesis pathways that
are common to most other bacteria, Chlamydia has a re-
duced genome size (~1 Mb) that requires the organism to
rely on the host cell for nutrients and survival [4]. As a re-
sult, Chlamydia’s obligate intracellular development cycle
had hampered progress towards genetic techniques and
the organism’s pathogenic mechanisms have not been fully
elucidated.
HtrA is a critical protease and chaperone for many bac-
teria and has been implicated in several functions including
stress response, protein quality control, outer membrane
protein (OMP) localization and assembly, host cell manipu-
lation, and virulence [5–9]. The distinct biochemical func-
tions of proteolysis and chaperone activity are mediated by
the allosteric activation of the protein to oligomers ranging
from trimers to hexamers to at least 24-mers [7, 10]. Using
homology modeling and biochemical methods, we have
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previously suggested that C. trachomatis HtrA (CtHtrA)
proteolytic activation and oligomerization are mediated
by distinct structural pathways, and that specificity of
the substrate binding may differentiate protease and
chaperone activity [11, 12]. HtrA is highly conserved in
Chlamydia and the application of a chemical inhibitor
of CtHtrA protease activity indicated that CtHtrA is im-
portant for the replicative phase of the chlamydial de-
velopmental cycle, important for the recovery from
penicillin-induced chlamydial persistence, and has a
critical role during heat stress [13–18]. These data, relying
on both biochemical and inhibitor-based approaches, en-
abled significant insight into CtHtrA function and the role
of specific parts of the amino acid sequence for these
functions, and provided the foundation for this attempt to
use genetics to investigate CtHtrA’s physiological role for
C. trachomatis.
In the absence of genetic techniques such as targeted
gene replacement and transposon-based mutagenesis,
the field has instead relied on genomic, proteomic, and
transcriptomic methods for chlamydial research. How-
ever, functional validation requires genetic evidence. In
response, several molecular strategies have recently
proven successful including small molecule inhibitors
[15, 19], random chemical mutagenesis [20], lateral gene
transfer [21], and shuttle vector transformations [22].
Given our existing data on the structure and function of
CtHtrA, genetic approaches such as random chemical
mutagenesis are a promising approach to for the charac-
terisation of CtHtrA in C. trachomatis.
Chemical mutagenesis is the use of chemical compounds
to increase the frequency of chromosomal mutations above
the spontaneous rate [23]. The types of DNA lesions pro-
duced include DNA adducts, intercalation, inter-strand
cross-linking, alkylation, and/or base modifications, which
result in base-pair substitutions, frameshift mutations, and/
or deletions in the nucleotide sequence. In 2011, Kari et al.
presented the development of a reverse genetics approach
using chemical mutagenesis to generate isogenic mutants
of C. trachomatis [24], demonstrating that EMS is a viable
mutagen for genetic studies in Chlamydia. EMS is an
alkylating agent that specifically acts at nitrogen positions
in nucleotide bases to produce GC to AT transition muta-
tions [25]; based on the GC content of the C. trachomatis
L2 434/Bu genome, there are 429,520 potential sites that
could theoretically be mutated by EMS. Thus, single nu-
cleotide variants (SNV), induced by the EMS treatment of
C. trachomatis, can be identified in a gene of interest and
subjected to a genetic characterization of its function.
Given our awareness of the residues and structural ele-
ments that are important for CtHtrA’s protease and
chaperone activity [11, 12, 17, 18], we investigated several
SNVs in the cthtrA gene to examine the protein’s physio-
logical function for C. trachomatis.
Methods
Chlamydial culture conditions
Chlamydia trachomatis was routinely cultured in
McCoy B or HEp-2 cells in the presence of DMEM sup-
plemented with 10 % fetal calf serum (FCS) at 37 °C, 5 %
CO2. Experiments were typically conducted at an MOI of
0.3. For the calculation of infectious yield, cultures har-
vested in SPG buffer (10 mM sodium phosphate, 250 mM
sucrose, 5 mM glutamic acid, pH 7.4) were serially diluted
and cultured in fresh McCoy B cell monolayers until 30 h
post-infection, when they were fixed with methanol and
stained for microscopy. The infectious yield was deter-
mined by the number of inclusion forming units from
each milliliter of the original culture.
Chemical mutagenesis
Chemical mutagenesis of C. trachomatis L2 was performed
by the Valdivia Laboratory at Duke University, NC, USA
[21]. Vero cells were infected with RifR C. trachomatis ser-
ovar LGV biovar L2 434/Bu at an MOI of 5.0 for 18 h and
exposed to 20 mg/mL ethyl methanesulfonate (EMS) in
PBS for 1 h, as described [21]. EMS was prepared in phos-
phate buffered saline (PBS) with 0.9 mM calcium chloride
and 0.49 mM magnesium chloride [26]. The cells were
washed three times in PBS + CaCl2/MgCl2 to remove re-
sidual mutagen and incubated in DMEM/5 % FCS at 37 °C
in a 5 % CO2 humidified incubator for 48–72 h to allow
the bacteria to recover and complete their developmental
cycle. EBs were harvested by hypotonic lysis of infected
cells with sterile water, followed by addition of 5× SPG
media to a final concentration of 1× SPG, titered for IFUs,
plaque-purified as described [21] and stored at−80 °C. The
frequency of mutagenesis was determined by inducing ri-
fampicin resistance, followed by the plaque purification
using 7 × 10-fold serial dilutions of bacteria in the presence
of 200 ng/mL rifampicin [26]. The frequency of rifampicin
resistance was defined as the number of rifampicin-
resistant plaques divided by the total number of bacteria
plated [26]. C. trachomatis L2 chlamydial mutant strains
containing SNVs in cthtrA were identified from whole gen-
ome sequences generated from a collection of 934 chem-
ically mutagenized C. trachomatis L2 strains (sourced from
the Valdivia laboratory for this study, investigated in the
Huston Lab in Australia). Isolates from this collection
containing cthtrA variants were further purified by plaque
isolation (in Australia).
C. trachomatis D was mutagenized four consecutive
times in the Caldwell Laboratory, NIAID Rocky Moun-
tain Laboratories, Montana. At each round, infected
McCoy cells were exposed to 5–7 mg/mL EMS 19 h
post-infection for 1 h and chlamydiae were harvested
40–44 h post-infection. A library of sub-populations
were built to screen for cthtrA mutants. McCoy B cells
in 96-well tissue culture plates were infected with 8
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inclusion-forming units per well. Chlamydiae were har-
vested at 48 h post-infection and were used to reinfect
McCoy B cells in 96-well tissue culture plates. Infected
cells were harvested and passaged for a third time, and
DNA extracted from the third passage was used to PCR
amplify cthtrA. Amplicons were heat denatured, slowly
reannealed, and digested by CEL I endonuclease. Diges-
tion products were visualized by DNA agarose gel elec-
trophoresis. Mutations detected by CEL I digestion were
identified by Sanger sequencing (these strains and this
work to identify the mutations was conducted in the
Caldwell laboratory, characterization of the strains was
conducted in the Huston laboratory).
In silico analysis of cthtrA SNVs
CtHtrA sequence alignments, 2D structural motifs, and
homology models for the hexameric and 24-meric oligo-
mers were used for the characterisation of EMS mutants,
as previously described [11]. Each mutation was examined
in both oligomeric models of CtHtrA with the PyMOL
Molecular Graphics System, Version 1.7.4 Schrödinger,
LLC, according to secondary structure localisation and
potential impact on CtHtrA function.
Site-directed mutagenesis and recombinant protein
expression
The previously generated CtHtrA recombinant expres-
sion construct was used for this study [17]. Site-directed
mutagenesis was used to introduce point mutations cor-
responding to the EMS mutations identified in the
chlamydial strains using a QuikChange II XL Site-
Directed Mutagenesis Kit (Stratagene) using the
primers A240Vsdm, E47Ksdm, G268Rsdm, G475Esdm,
P370Lsdm, and R55Qsdm (Additional file 1: Table S4).
All mutations were confirmed by Sanger sequencing.
Heterologous recombinant protein expression and
purification of CtHtrA recombinant mutated proteins
were completed as previously published [11, 12, 17].
Protease assays
Full-length β-casein cleavage assays were initially used to
test the proteolytic activity of wild type CtHtrA and the
mutants. Up to 2 mg of recombinant CtHtrA was incu-
bated with 10 mg of β-casein in 50 mM Tris, 20 mM
MgCl2 and examined with SDS-PAGE as previously de-
scribed [17]. The gel bands were quantified by densitom-
etry using a Li-Cor Odyssey 9120 Infrared Imaging
System. The rate of proteolysis was tested with a peptide
substrate labelled with 7-methoxycoumarin-4-acetic acid
(MCA; fluorophore) and 2,4-dinitrophenyl (DNP;
quencher) in black plates at 37 °C using a POLARstar
Optima D77656 fluorimeter. Substrate specificity was
examined using peptides labelled with para-Nitroanilide
(pNA) that were incubated with CtHtrA at 37 °C and
analysed with an xMARK microplate spectrophotometer.
All protein and peptide substrates and allosteric acti-
vators are listed in Additional file 1: Table S5. All pep-
tides and activators were synthesised by Mimotopes
(Melbourne, VIC, Australia) to 95 % purity and were re-
suspended in 50 % isopropanol or DMSO. Statistical
analyses were conducted using an unpaired t-test, calcu-
lated with Prism software. All assays were conducted on
two separate occasions, in triplicate.
Oligomerization assays
The ability of CtHtrA or the mutants to oligomerize to
higher oligomers was examined by crosslinking oligomers
with glutaraldehyde as previously described [12]. The sam-
ples were separated on 3–8 % Tris-Acetate gradient poly-
acrylamide gels and examined by silver staining. All assays
were conducted in triplicate on three separate occasions.
HiMark pre-stained molecular weight marker (Life Tech-
nologies, USA) was included on each gel.
Heat shock of chlamydial culture
Heat shock assays were performed by infecting HEp-2
cells in a 48-well plate with CtL2wt and each mutant at
an MOI of 0.3 in DMEM at 37 °C, 5 % CO2. Cultures
were heat shocked for 4 h at 42 °C, 5 % CO2 beginning
at 20 h post-infection, before returning the cultures to
37 °C for the remainder of the development cycle, prior
to the measurement of infectious progeny [14].
Chlamydia growth curves
Growth curve assays were performed by infecting
McCoy B cells in a 96-well plate with CtL2wt and each
of the mutants at an MOI of 0.3. The cells were incu-
bated in DMEM at 37 °C, 5 % CO2 for up to 48 h. At
each time point the cultures were harvested by media re-
moval, the addition 200 μL SPG, and storage at −80 °C.
The plates were thawed and the McCoy B cells lysed by
pipette disruption and cell lysates for each time point were
serially diluted and used to re-infect fresh McCoy B cell
monolayers in DMEM + 1 μg/mL cycloheximide on
96-well plates, in triplicate. The infectious yield was
determined as described above.
Morphological analysis and immunocytochemistry
Chlamydia cultures were visualised with immunofluores-
cence as previously described [16, 27]. Briefly, confluent
McCoy B cells seeded on 8 mm coverslips in a 48-well
plate were infected with Chlamydia at an MOI of 0.3 in
DMEM media and were stained with the Chlamydia Cel
LPS product (Cellabs, Brookvale, NSW, Australia) as per
the manufacturer’s instructions. Primary antibody was in-
cubated for 1 h in 1 % BSA followed by two washes in PBS.
Secondary antibodies were Alexa Fluor 488 goat anti-
rabbit (Life Technologies, USA) and were used at 1/600
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dilution in 1 % BSA for 1 h. Coverslips were mounted
using Prolong Gold antifade (Life Technologies, USA) and
viewed under a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems). Images were captured
using the Leica application suite for advanced fluorescence.
Genetic analysis of C. trachomatis strains with EMS
generated mutations
CtL2wt and mutants were semi-purified and genomic DNA
was extracted using the phenol-chloroform method as pre-
viously described [28]. Whole genome sequencing was per-
formed commercially by the Micromon sequencing facility
on the Illumina MiSeq platform, using theTruSeq v3 chem-
istry and the NexteraXT Library Preparation Kit (Monash
University, Victoria, Australia). SNV analysis was performed
using Nesoni (https://github.com/Victorian-Bioinformatics-
Consortium/nesoni) with the C. trachomatis L2 434/Bu
complete genome (RefSeq accession: NC_010287) serving
as the reference sequence.
Lateral gene transfer
Spectinomycin-resistant (SpcR) C. trachomatis L2 iso-
lates and rifampicin-resistant (RifR) mutant isolates
were generated by repeated passage on McCoy B cells
in the presence of sub-inhibitory concentrations of
the antibiotic. Passaging continued until maximum re-
sistance was reached in the presence of 200 ng/mL ri-
fampicin or 200 μg/mL spectinomycin. Lateral gene
transfer between the SpcR CtL2wt and Rif
R mutant
was induced by co-infecting each strain at an MOI of
4.0 in 12 wells of a 24-well plate (total MOI of 8.0).
Positive controls were included by infecting duplicate
wells in the presence of rifampicin only or spectino-
mycin only. Negative control wells with no antibiotics
were also included. The cell lysates from each well
were serially diluted and used to infect a fresh McCoy
B cell monolayer on 6-well plates for plaque purifica-
tion cultures [21].
Results
Chemical mutagenesis allows identification of SNVs that
impact on CtHtrA function
Two existing libraries of C. trachomatis mutants were
screened for mutations in the cthtrA gene, one based on
C. trachomatis serovar L2 (CTL0195) and the other on
C. trachomatis serovar D (CT_823). The screening of
two libraries was performed to enable enable higher
coverage of the cthtrA gene, while enabling the reduc-
tion of possible SNV bias given that the libraries were
prepared using different methods. The C. trachomatis
L2 and D serovars share 99.5 % nucleotide identity and
99.4 % amino acid identity at the cthtrA locus and thus
are not expected to exhibit functional differences.
Firstly, we determined that there were 797 C/G to T/A
mutations possible in cthtrA; 601 would be non-
synonymous, 160 synonymous, and 36 nonsense. We
have previously used a chemical inhibition approach to
demonstrate that CtHtrA is critical for the survival of
C. trachomatis [15], so it was expected that strains
harboring null mutations in cthtrA would be non-
viable. However, strains containing cthtrA alleles with
non-synonymous mutations in functionally important res-
idues could potentially be used to investigate CtHtrA
physiological function(s). The first library screened was a
collection of 937 C. trachomatis serovar L2 (434/Bu) mu-
tant strains in which each SNV was mapped by whole
genome sequencing. This library was generated with a
mutation frequency ranging from 6 to 25 mutations per
genome following treatment with EMS and ENU [29].
The second library screened was based on C. trachomatis
serovar D-LC (CtD-LC) [30] and included ~4600 mutant
strains with a mutation frequency of seven SNVs per gen-
ome. Between the two libraries a total of 5537 mutants
were screened and a total of 52 cthtrA variants were iden-
tified (Additional file 1: Table S1). Eighteen variants had
synonymous substitutions and were excluded from further
analysis, while the remaining 35 were analyzed in silico to
predict their functional impact based on our previous in
silico and biochemical understanding of the CtHtrA amino
acid sequence and associated functions [11, 12].
Three CtHtrA mutations have an impact on in vitro
proteolysis but not oligomerization
The cthtrA EMS mutations were examined using molecu-
lar models of the inactive hexamer and active 24-mer olig-
omers of CtHtrA, according to 2D and 3D structural
motifs known to have a role in CtHtrA protein function
[11, 12, 17, 18]. Mutations were identified throughout the
entire cthtrA gene, with SNVs identified in the signal
peptide, protease domain, PDZ1 domain, and PDZ2 do-
main (Additional file 1: Table S1). Six mutations that
resulted in amino acid substitutions were selected for
characterization based on in silico prediction of a struc-
tural and/or functional impact: E47K (G – A), R55Q (G
– A), A240V (C – T), G268R (G – A), P370L (C – T),
and G475E (G – A) (Fig. 1a). The E47K and R55Q mu-
tations were located at the N-terminus of the protease
domain, upstream from loop LA, and had the potential
to disrupt the trimeric protease domain interface by form-
ing a steric clash with an adjacent protease domain loop
(Fig. 1b). A240V represented a minor substitution from
alanine to valine, two small and hydrophobic amino acids,
however this residue is situated on loop L1 near to the
catalytic serine and any conformational shift that may
occur as a result of this mutation, however minor, would
likely impact CtHtrA proteolytic activity (Fig. 1b). G268R
was situated in the protease domain active site in loop L2
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and potentially results in a steric clash with loop L2 from
an adjacent protease domain, also potentially disrupting
proteolysis (Fig. 1b). P370L was located in the PDZ1 do-
main at the base of the ‘carboxylate binding loop’ and is
likely to disrupt the conformational turn of this loop,
which may impact the binding of the substrate C-terminus
to the PDZ1 domain and the subsequent activation cascade
(Fig. 1b). G475E was located in the PDZ2 domain and
resulted in a potential steric clash with a nearby PDZ2 do-
main loop, as well as an adjacent PDZ1 domain in the olig-
omeric state, thus potentially affecting the oligomerization
mechanism (Fig. 1b). These six mutations were then gener-
ated in vitro in our CtHtrA recombinant protein expression
construct using site-directed mutagenesis for biochemical
characterization of the recombinant mutated proteins.
The proteolysis and oligomerization activities of these
recombinant proteins were compared to the wild-type re-
combinant protein (CtHtrA). All recombinant proteins
were able to cleave full-length β-casein at 37 °C, with
proteins CtHtrAE47K, CtHtrAG268R, and CtHtrAR55Q
displaying similar proteolytic activity to the wild-type
(Fig. 2a). The rate of proteolysis was slower for the
CtHtrAA240V, and CtHtrAG475E proteins compared to the
wild type, while the proteolysis activity of the CtHtrAP370L
was substantially reduced (Fig. 2a; Additional file 2: Figure
S1). Similarly, in the presence of a peptide substrate, the
CtHtrAA240V and CtHtrAG475E proteins demonstrated a
reduction in proteolytic rate, respectively, compared to
the wild-type, while no proteolytic activity could be de-
tected for the CtHtrAP370L protein (Fig. 2b). The proteo-
lytic rate of the CtHtrAG268R and CtHtrAR55Q proteins
were not substantially different from the wild-type. We
have previously shown that the addition of a second pep-
tide based on the 12 C-terminal residues of β-casein
(Act1) can activate or increase the proteolytic activity of
CtHtrA [11, 12]. Thus, the activation of proteolysis by the
recombinant proteins was investigated and a 1.4–2.3-fold
increase in the rate of proteolysis was observed for
CtHtrAE47K, CtHtrAG268R, CtHtrAR55Q, CtHtrAA240V and
CtHtrAG475E. Alternatively, CtHtrAP370L displayed no
Fig. 1 Mutated residues shown on the CtHtrA monomer of the active 24-meric structure. a. The CtHtrA active monomer with black boxes indicating the
location of mutated residues. Green: protease domain, orange: PDZ1 domain, blue: PDZ2 domain. b. Close-up of wild-type residues (orange side-chain)
aligned with the mutated residue (green side-chain)
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detectable proteolytic activity against this peptide sub-
strate (Fig. 2b), which may be due to this mutation causing
a conformational change to the ‘PDZ1 activation cleft’,
impacting the correct binding of Act1. Substrate specifi-
city of the proteins was also examined using different
para-Nitroanilide (pNA)-labeled substrates that differ in
length and sequence (P1 – P4). No differences in substrate
specificity were observed for any of the proteins compared
to the wild type, suggesting that the mutations do not ap-
preciably change the conformation of the catalytic domain
(at least using these substrates; Fig. 2c). The CtHtrAP370L
protein again displayed no proteolytic activity. CtHtrA has
been previously shown to oligomerize from a resting hex-
amer to an activated 12–/24-mer in the presence of both
peptide and protein substrates [11, 12]. To investigate
whether any of the recombinant mutated protein disrupted
or impaired the activation of oligomerization, each were
incubated with full-length β-casein at 37 °C and cross-
linked with glutaraldehyde. In the presence of substrate,
each mutant formed particles that are consistent with a
higher order oligomer of CtHtrA (such as a 24-mer), with
no evidence of the hexameric or trimeric forms that are
observed when the oligomerization mechanism has been
disrupted [12, 31]. While this method cannot detect differ-
ences in oligomeric structure or the exact number of
monomers present, oligomeric activation to some form of
oligomer appears to be unperturbed for each of the mu-
tants (Fig. 2d) [11]. These data demonstrated that the
CtHtrAA240V, CtHtrAG475E, and CtHtrAP370L mutations
resulted in an appreciable disruption to the in vitro pro-
teolytic activity of CtHtrA and therefore isolates with these
three mutations were selected from the libraries for fur-
ther in vitro analysis of their phenotypic impact on chla-
mydial growth.
Fig. 2 In vitro biochemical activity of wild type C. trachomatis L2 and recombinant mutants. a. Cleavage of full-length β-casein by wild type CtHtrA and
recombinant mutants over a 60 min time course. The corresponding SDS-PAGE gels are provided in Additional file 2: Figure S1. b. Rate of proteolysis of
the βcas1 peptide substrate with and without allosteric activation (Act1 peptide) by recombinant proteins. Numbers above the bars represent
the fold-change in proteolytic activity following the addition of the Act1 activator. Rate of proteolysis is measured as μM MCA min−1 μg CtHtrA−1. Error
bars represent standard error of the mean (n= 6). c. Measurement of the proteolytic activity of wild type CtHtrA and mutants in the presence of pNA1-4
peptide substrates. Rate of proteolysis is measured as pNA 405 nm min−1. Error bars represent standard error of the mean (n= 6). d. Wild type CtHtrA and
the mutants oligomerise to 24-mer in the presence of full-length β-casein. The figure shows glutaraldehyde crosslinked protein samples prepared by
oligomerisation assays following separation on 3–8 % TrisAcetate gels prior to silver staining. The size of the 24-meric oligomer is indicated to the right of
the gel and the molecular weights are indicated on the left (High Molecular Weight Marker, Invitrogen)
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A strain with a P370L substitution in cthtrA exhibits
decreased or delayed EB production
Previous work by our group suggested that CtHtrA has a
crucial role in the replicative phase of C. trachomatis devel-
opment, as the JO146 CtHtrA inhibitor was lethal when
added to the cultures at mid-replication [15]. Accordingly,
growth rates were assessed for Chlamydia strains contain-
ing the cthtrA variants cthtrAA240V, cthtrAP370L, cthtrAG475E
and wild-type C. trachomatis serovar L2 (referred to as for
this study CtL2wt) (Additional file 1: Table S2), by deter-
mining the time at which infectious EBs were first de-
tected, with additional times points during the growth
cycle. The presence of infectious EBs was detected between
20 and 48 h post-infection, with each mutant strain produ-
cing fewer EBs than the wild-type (Fig. 3a). The cthtrAP370L
mutant produced significantly fewer infectious EBs
compared to the wild type and other mutants, display-
ing a ~20–40-fold reduction (~95 % reduction) in infec-
tious EB progeny (for example at 32 h post infection,
2.26 × 107 EBs were detected for CtL2wt while 5.45 × 10
5
EBs were detected for cthtrAP370L, corresponding to a
41.4-fold reduction in infectious EB production at this
time point).
The C. trachomatis isolate harboring a P370L substitution
in cthtrA displays increased susceptibility to heat shock
The role of bacterial HtrA during heat shock has been
widely reported [32–34], and CtHtrA in particular has
been shown to be upregulated during heat stress condi-
tions [16] and critical for heat stress survival when the
chemical inhibitor against CtHtrA was used [14].
Therefore, Chlamydia strains with functionally disrup-
tive mutations in cthtrA are likely to be more severely
impacted by heat stress. HEp-2 cells were infected with
each strain and subjected to 42 °C heat shock during
the replicative phase (20 h post-infection) for 4 h, prior
to restoration to 37 °C for the remainder of the devel-
opment cycle. The impact of heat shock treatment on
the mutants was determined by calculating the subse-
quent infectious yield from cultures harvested at 44 h
post infection. The cthtrAA240V mutant had an infec-
tious yield that was comparable to the wild-type, while
both the cthtrAG475E and cthtrAP370L mutants exhibited
a significant reduction in infectious yield following heat
shock, relative to the wild-type (Fig. 3). Notably, the
cthtrAP370L mutant resulted in a 32.5-fold reduction in
infectious EB yield following heat shock compared to
the wild type (p < 0.0001).
The cthtrAP370L inclusions are smaller in size
The impact of the mutations on the chlamydial inclusion
morphology was examined using immunocytochemistry
and confocal laser scanning microscopy. Cultures were ex-
amined at 24 h post-infection (log phase) and 40 h post-
infection (stationary phase; Fig. 4). At 24 h post-infection,
the inclusion size of each mutant appeared smaller com-
pared to the wild-type, while in the cthtrAP370L strain there
appeared to be fewer chlamydial cells within the inclusions.
At 40 h post-infection, the inclusion sizes appeared to be
more comparable to the wild-type, if slightly smaller. The
inclusion sizes were measured to allow statistical compari-
son of the mutants against the wild-type, confirming that
the mutant inclusion sizes were appreciably smaller com-
pared to the wild-type at 24 h post-infection (Fig. 5). The
difference was less pronounced at 40 h post-infection,
where the cthtrAG475E inclusion sizes were not significantly
different compared to the wild-type. Alternatively, in the
cthtrAA240V and, to a greater extent, cthtrAP370L strains, in-
clusion sizes were significantly smaller than the wild-type
(p < 0.0001; Fig. 5).
Genomics and lateral gene transfer to isolate chlamydial
SNVs for further characterization resulted in a ctl0738null
but not a cthtrAP370L isogenic strain
While these observed phenotypes are consistent with
our previous observations for CtHtrA function, it is
likely that the additional SNVs present in these mutant
genomes also contribute to the phenotype. As a result,
Fig. 3 Growth and heat shock response phenotypes for C. trachomatis
mutants containing cthtrA SNVs. a. One-step growth curve for CtL2wt
and mutants over a 48 h time course. McCoy B cells were infected at
an MOI of 0.3 and collected over the time course for determination of
inclusion-forming units (IFUs). b. Infectious yield of CtL2wt and mutants
at 44 h post infection after 4 h heat shock (42 °C, 5 % CO2; 20–24 h
post infection). **** indicates p < 0.0001. Error bars represent standard
error of the mean (n = 27)
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the genome sequences of the cthtrAA240V, cthtrAG475E,
and cthtrAP370L mutants were determined by whole gen-
ome sequencing (WGS). When compared to the CtL2wt
genome sequence, the mutants consisted SNVs at nine
loci that were consistent in all three isolates (cthtrAA240V,
cthtrAG475E, and cthtrAP370L): ctl0103, nusA, ctl0518, clpC-
1, clpC-2, rpoB, pykF, and pmpC, which were confirmed to
originate from the CtL2rif strain used to generate the
library (Additional file 1: Table S2) and were thus not ex-
pected to contribute to the observed phenotypes. Alterna-
tively, we observed 13 unique SNVs in the cthtrAA240V
(including the A240V C – T transition at position 247526
in cthtrA), 19 unique SNVs in the cthtrAP370L isolate (in-
cluding the P370L C – T transition at position 247916 in
cthtrA), and eight unique SNVs in the cthtrAG475E isolate
(including the G475E G – A transition at position 248231
in cthtrA; Additional file 1: Table S3), which could poten-
tially contribute to the observed phenotypes.
Given that the isolate with the cthtrAP370L mutation dis-
played the most marked phenotypes and was severely im-
paired during CtHtrA recombinant protein in vitro
protease assays, it was reasoned that this isolate will be the
most informative for determining the physiological func-
tion of CtHtrA and was selected for further genetic
Fig. 4 Confocal microscopy images of CtL2wt and mutants at 24 h and 44 h post infection. The Chlamydia isolates (CtL2wt and mutant) are shown to
the left of the panels and the time point is shown above the panels. The second and fourth images for each isolate are enlarged representations of
single inclusions. The image colours are, green: LPS (FITC anti-chlamydial LPS); red: host cells (Evans blue). The scale bars (bottom right) indicate 50 μm
and 25 μm for the enlarged images
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characterization. Of the 19 unique SNVs in the genome of
the cthtrAP370L mutant isolate, 11 were non-synonymous,
five were synonymous, and three were located in intergenic
regions. Notably, there was a null mutation in ctl0738, a
putative DNA methyltransferase. Of the eleven non-
synonymous mutations, three resulted in a change to a
similar amino acid (i.e. polar, hydrophobic etc.) and are
therefore unlikely to have a functional effect (these were
SNVs found in ctl0493, metG, and ctl0220). Consequently,
a total of eight SNVs in the following cthtrAP370L isolate
were identified as potentially significant, found on the fol-
lowing locus: recB, murC, incA, ydhO, ctl0738 (putative
DNA methyltransferase), ctl0791 (putative membrane
protein), ctl0885 (conserved hypothetical protein), and
cthtrAP370L (Fig. 6, Additional file 1: Table S3).
In an effort to separate the cthtrAP370L SNV from
these remaining SNVs, a lateral gene transfer approach
was utilized, by co-infecting host cells with the rifampi-
cin resistant cthtrAP370L stain and a spectinomycin re-
sistant CtL2wt strain to generate recombinant isolates
[21]. Positive recombinants were selected by plaque purifi-
cation in the presence of both antibiotics. PCR and Sanger
sequencing was conducted on 56 plaque-purified double
resistant recombinant strains for the cthtrAP370L SNV and
ctl738null (DNA methyltransferase), in addition to the other
SNVs identified as potentially significant. The cthtrAP370L
SNV was not detected in any of the 56 plaque purified re-
combinant isolates, while the ctl0738null SNV was variously
distributed among the recombinants. One recombinant
isolate (ctl0738null) contained the ctl0738 SNV and
none of the other seven SNVs, allowing the potential
for characterization of the DNA methyltransferase null
mutation in the absence of the cthtrAP370L and
remaining SNVs.
Characterization of the ctl0738null mutation suggests that
the cthtrAP370L SNV is the major contributor to the
reduced infectious progeny phenotype
The lateral gene transfer experiments did not enable the
generation of an isogenic cthtrAP370L mutant isolate. The
SNV that could be contributing to the phenotype ob-
served in the cthtrAP370L strain was the null mutation in
the DNA methyltransferase, ctl0738. This mutation was
able to be transferred to the genome of C. trachomatis L2
spectinomycin-resistant strain (CtL2spc) in the absence of
the eight other EMS mutations that were considered po-
tentially significant on the ctHtrAP370L isolate genome.
Therefore, further analysis of the isogenic strain contain-
ing the DNA methyltransferase null (ctl0738null) was con-
ducted to examine the role of this mutation for the
phenotypes observed in the cthtrAP370L strain. Growth
curve and heat shock experiments were conducted using
the wild type strains (CtL2wt and CtL2spc), the original
cthtrAP370L mutant strain, and the ctl0738null strain. The
cthtrAP370L strain has the same severely impacted reduced
infectious progeny yield (8–25-fold reduction in infectious
progeny; Fig. 7a) and the ctl0738null strain showed infec-
tious progeny production similar to the wild type. Notably,
by including additional time-points at the beginning of
the replicative phase (16–22 h post infection), it was
observed that both the cthtrAP370L and ctl0738null
strains displayed a delayed start to the log growth phase
implying slowed RB to EB conversion. Somewhat unex-
pectedly, the heat stress phenotype was similar in the
cthtrAP370L and ctl0738null strains with a significant
reduction in infectious progeny (CtL2wt: 4.5 × 10
7
EBs, cthtrAP370L: 1.2 × 10
6 EBs; ctl0738null: 1.4 × 10
6
EBs; p < 0.0001), corresponding with a 30–40-fold re-
duction in infectious progeny after heat stress rela-
tive to CtL2wt (Fig. 7b).
Discussion
Here we present genetic evidence that cthtrA has a role
in the production of infectious EBs. There are a number
of possible conclusions that could be hypothesized based
on the results presented here. Firstly, we did not find
cthtrA alleles with null mutations in either library, so it
is tempting to speculate that such a mutation would not
be viable, however, considerably greater numbers of mu-
tant strains would need to be screened before we could
conclude with confidence that null mutations in cthtrA
are not permissible. Although, we have previously dem-
onstrated that a CtHtrA specific chemical inhibitor of its
protease activity is completely lethal when added during
Fig. 5 Inclusion sizes of CtL2wt and mutants at 24 h and 44 h post
infection. Inclusion sizes were measured from independent coverslips.
****indicates p< 0.0001. Error bars represent standard error of the
mean (n= 27)
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the replicative phase of the developmental cycle [15],
which supports that it may not be possible to isolate
strains with null mutation in cthtrA.
We were able to identify a strain with a SNV resulting in
an amino acid substitution (P370L) in the cthtrA sequence,
that resulted in a severe reduction in proteolytic activity in
the recombinant protein bearing the substitution. However,
we expect there is some proteolytic activity by this form of
CtHtrA (cthtrAP370L) in vivo. Firstly, our in vitro assays are
based on model substrates requiring a second peptide for
allosteric activation of maximal protease activity and thus
may not accurately reflect in vivo activity. Secondly, the
assay against the full-length β-casein protein demonstrated
in vitro protease activity for this mutated protein, suggest-
ing that in vivo activity is likely to be present. Given that
the strain is still viable and that chemical inhibition of the
proteolysis activity of CtHtrA was found to be lethal [15],
we suspect some CtHtrA proteolysis activity is occurring
in vivo in this strain (cthtrAP370L). While causality will re-
quire additional genetic evidence, this mutation to be a
major contributor to the severe defect in the production of
infectious EBs we observed in the cthtrAP370L mutant
strain (20–40-fold reduction), that was not contributed to
by the ctl0738 SNV (as this was not observed in the
ctl0738null strain generated by lateral gene transfer).
The cthtrAP370L strain had 18 SNVS compared to 11
and 8 SNVs detected in the cthtrAA240V, cthtrAG475E
strains respectively, and hence, while it is tempting to at-
tribute the phenotypes observed to the P370L mutation, it
could in fact be a consequence of a combination of muta-
tions or one of the other mutations alone. However, we
can be confident that the reduced infectious EB produc-
tion phenotype is not a consequence of the ctl0738null mu-
tation, based on the data in Fig. 7a. It was surprising to
observe that the ctl0738null strain showed similar reduced
infectious EB yield after heat stress as the cthtrAP370L iso-
late, as this model of stress is not expected to induce
DNA damage that would require the repair enzyme pre-
dicted to be encoded by this locus [35].
Perhaps the most important result is that after lateral
gene transfer experiments and the screening of 56 plaque
purified isolates, no strain was identified containing the
P370L mutation (C – T at nucleotide position 247916).
This could be random chance or could suggest that the
Fig. 6 Circular representation of the reference L2/434/Bu genome (1.04 Mbp) showing the position of SNVs found on protein coding genes and
the annotation of those genes. Each mutant strain is represented by a single ring layer (from inner to outer: cthtrAP3470L, cthtrAG475E, cthtraA240V).
Blue labels correspond to synonymous SNVs and black labels indicate non-synonymous SNVs. Figure generated using BRIG [37]
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P370L mutation in isolation is responsible for a severe
growth defect that prevented us from isolating any strains
during these experiments. Alternatively, it is possible that
one of the other SNVs is suppressing the P370L mutation
in the cthtrAP370L strain. Given that we expect CtHtrA’s
function to impact the integrity of several chlamydial cell
envelope proteins, including major outer membrane
protein (MOMP), Porin B (PorB), and the polymorphic
membrane proteins (Pmps) [12], CtHtrA’s chaperone and
protease activity as a stress response and housekeeping pro-
tein important for outer membrane protein assembly could
be indirectly driving the observed phenotypes [31, 36].
The smaller inclusion sizes observed in the cthtrAP370L
strain corresponds with the reduced infectious EB yield
suggesting a growth defect (possibly relating to optimal
replication) could be a consequence of reduced CtHtrA
function, likely indirectly due to the function of a sub-
strate that requires CtHtrA for correct assembly or
maintenance.
Overall, we have provided genetic evidence that C.
trachomatis with a genetic mutation (C – T at position
247916 in cthtrA) likely resulted in reduced production
of infectious EB, potentially correlating with a negative
impact of this mutation on CtHtrA’s in vitro proteolytic
activity. While genetic causality could not be con-
firmed, these results provide further evidence that
CtHtrA has a critical role during the developmental
cycle of Chlamydia.
Conclusions
HtrA is known to be an important protease for many
bacterial pathogens. Analysis of Chlamydia trachoma-
tis genetic mutants possessing variants of the cthtrA
gene that firstly showed an impact on proteolytic func-
tion by in vitro analysis demonstrated that these mutants
had reduced infectious progeny. Thus HtrA has a critical
role in formation of chlamydial infectious progeny.
Availability of supporting data
Supplementary tables are provided. The draft assemblies
of all genome sequences generated during this project
are available through the EMBL ENA database under
the Study number PRJEB9044: http://www.ebi.ac.uk/ena/
data/search?query=PRJEB9044.
Additional files
Additional file 1: Table S1. EMS library mutants with confirmed
non-synonymous SNVs in the cthtrA gene. Table S2. List of bacterial
strains used in this study. Table S3. Total SNVs present in the cthtrAA240V,
cthtrAP370L, and cthtrAG475E mutants as confirmed by whole genome
sequencing. Table S4. Sequences and associated annealing temperatures
for the PCR primers used in this study. Table S5. Active site substrates and
activators used for proteolysis and oligomerisation assays. (DOCX 45 kb)
Additional file 2: Figure S1. SDS-PAGE gels of full length β-casein
cleavage by wild type CtHtrA and mutants over a 60 min time course. A.
Wild-type CtHtrA; B. CtHtrAA240V; C. CtHtrAE47K; D. CtHtrAG268R; E. CtHtrAG475E;
F. CtHtrAP370L; G. CtHtrAR55Q. Lanes are labelled: M: protein molecular weight
marker (Bio-Rad); 0 min; 10 min; 20 min; 30 min; 40 min; 50 min; 60 min; H:
Fig. 7 Cell culture analysis of growth and heat shock phenotypes for the cthtrAP370L and ctl0738null mutants. a. One-step growth curve for wild-type C.
trachomatis L2 and mutants over an 88 h time course. McCoy B cells were infected at an MOI of 0.3 and collected over the time course for determination
of inclusion-forming units. b. Viable infectious yield of wild-type C. trachomatis L2 and mutants at 44 h post infection after 4 h heat shock (42 °C, 5 %
CO2; 20–24 h post infection). ****indicates p < 0.0001. Error bars represent standard error of the mean (n–27)
Marsh et al. BMC Microbiology  (2015) 15:194 Page 11 of 13
CtHtrA only; βc: β-casein only. The molecular masses of standard proteins
are indicated by arrows next to the gels. (DOC 21 kb)
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